Three-Year Efficacy, Safety, And Survival Findings From Comfort-Ii, A Phase 3 Study Comparing Ruxolitinib With Best Available Therapy For Myelofibrosis (Vol 122, Pg 4047, 2013)F. Cervantes,A. M. Vannucchi,J-J KiladjianBLOOD（2016）引用 317|浏览3暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
